💊 Can understanding receptor bias help us design safer, more selective GPCR drugs?

🔗 Biased activation of the vasopressin V2 receptor probed by molecular dynamics simulations, NMR and pharmacological studies. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2024.10.039

📚 CSBJ: https://www.csbj.org/

#GPCR #StructuralBiology #MolecularDynamics #NMR #Pharmacology #ProteinStructure #DrugDiscovery #ComputationalBiology #CellSignaling

PhD Student and Postdoc Positions in Tissue Patterning and Regeneration

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
PhD Student and Postdoc Positions in Tissue Patterning and Regeneration

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
PhD Student and Postdoc Positions in Tissue Patterning and Regeneration

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv
PhD Student and Postdoc Positions in Tissue Patterning and Regeneration

Post a job in 3min, or find thousands of job offers like this one at jobRxiv!

jobRxiv

📣📣📣 Latest news from the NephroLab Cologne – more specifically, from our 🦛 Hippo- Team:
Our snRNA-Seq study on YAP and TAZ in kidney podocytes is now online open access in JASN! 🥳 🎉 🐙
Huge thanks to everyone on the team and the incredibly thorough reviewers at JASN!

Link: https://journals.lww.com/jasn/abstract/9900/transcriptional_regulators_yap_and_taz_have.598.aspx

#HippoSignaling #YAP #TAZ #Kidney #Kidneydisease #Science #snRNASeq #cellsignaling #FSGS #podocyte #Nephrology #Niere #Nephrolab #Nephrologie

@ukkoeln @UniKoeln @CECAD

The Basics of Purines and Pyrimidines: Understanding the Building Blocks of DNA and RNA

#Adenine, #CellSignaling, #Cytosine, #DNA, #EnzymeRegulation, #Guanine, #Purines, #Pyrimidines, #RNA, #Thymine, #Uracil #Genetics In the realm of molecular biology, few molecules are as crucial as purines and pyrimidines. These organic compounds serve as…. Medical Microbiology & Recombinant DNA Technology (RDT) Labs | Read More -

https://micrordt.wordpress.com/2024/05/15/the-basics-of-purines-and-pyrimidines-understanding-the-building-blocks-of-dna-and-rna/

The Basics of Purines and Pyrimidines: Understanding the Building Blocks of DNA and RNA

#Adenine, #CellSignaling, #Cytosine, #DNA, #EnzymeRegulation, #Guanine, #Purines, #Pyrimidines, #RNA, #Thymine, #Uracil #Genetics In the realm of molecular biology, few molecules are as crucial as …

Medical Microbiology & RDT Labs

Unveiling the Architect of Life: Exploring the Plasma Membrane

#CellAdhesion, #CellMembrane, #CellSignaling, #Communication, #Disease, #Homeostasis, #LipidByLayer, #Pathology, #PlasmaMembrane, #SelectivePermeability, #SemiPermeableMembrane, #UnitMembrane #CellBiology Composed primarily of lipids, proteins, and carbohydrates, the plasma membrane exhibits a dynamic and heterogeneous structure. Phospholipids, with their hydrophilic heads and hydrophobic tails, form the…

https://micrordt.wordpress.com/2024/04/25/unveiling-the-architect-of-life-exploring-the-plasma-membrane/

Unveiling the Architect of Life: Exploring the Plasma Membrane

#CellAdhesion, #CellMembrane, #CellSignaling, #Communication, #Disease, #Homeostasis, #LipidByLayer, #Pathology, #PlasmaMembrane, #SelectivePermeability, #SemiPermeableMembrane, #UnitMembrane #Cell…

Medical Microbiology & RDT Labs
@gpollara Is there a comprehensive resource that investigates the interferon signalling "landscape", also in conjunction with other microenvironmental pathways like cGAS or STING etc.? #cytokines #networks #CellSignaling #immunology #infection #immunotherapy

A developer of treatments for Alzheimer's disease that seeks to improve the condition of the brain's support cells is raising £48 million ($US 61 million) in its first venture round.

https://sciencebusiness.technewslit.com/?p=45307

#News #Press #Science #Business #Biotechnology #Neuroscience #AlzheimersDisease #Dementia #Astrocytes #Neurodegenerative #CellSignaling #Licensing #Finance #VentureCapital

Neuro Disease Biotech Gains $61M in Early Funds

A developer of treatments for Alzheimer's disease that seeks to improve the condition of the brain's support cells is raising £48 million ($US 61 million) in its first venture round.

Science and Enterprise